Trials / Conditions / Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma

22 registered clinical trials studyying Newly Diagnosed Multiple Myeloma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Suspended	Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation NCT06348147	UNC Lineberger Comprehensive Cancer Center	Phase 2
Not Yet Recruiting	ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligibl NCT07247097	Massachusetts General Hospital	Phase 2
Not Yet Recruiting	A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexa NCT06895512	Shanghai Henlius Biotech	Phase 3
Not Yet Recruiting	A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnose NCT06799676	Fuling Zhou	Phase 1 / Phase 2
Recruiting	A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus D NCT06679101	GlaxoSmithKline	Phase 3
Recruiting	Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients NCT06682156	The First Affiliated Hospital of Soochow University	—
Unknown	Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation NCT06324266	Jinling Hospital, China	Phase 2 / Phase 3
Recruiting	Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients NCT05665140	University Hopsital Schleswig Holstein Campus Lübeck	Phase 2 / Phase 3
Unknown	Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in NCT05561049	The First Affiliated Hospital of Soochow University	—
Not Yet Recruiting	NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide NCT05558319	PETHEMA Foundation	Phase 3
Recruiting	Biomarkers in Multiple Myeloma NCT05259553	Centre Hospitalier Universitaire de Saint Etienne	N/A
Unknown	A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagn NCT05088330	The First Affiliated Hospital of Soochow University	N/A
Active Not Recruiting	Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM NCT04891809	Arbeitsgemeinschaft medikamentoese Tumortherapie	Phase 2
Withdrawn	Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients NCT04348006	Al-Rasheed University College	Phase 4
Active Not Recruiting	Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM NCT04052880	Larysa Sanchez	Phase 2
Terminated	Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients NCT03733691	Oncotherapeutics	Phase 2
Active Not Recruiting	Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years NCT03742297	PETHEMA Foundation	Phase 3
Active Not Recruiting	Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM NCT03948035	Wuerzburg University Hospital	Phase 3
Completed	Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial M NCT01936532	Nantes University Hospital	Phase 2
Completed	Multiple Myeloma and Exercise NCT01809717	Abramson Cancer Center at Penn Medicine	N/A
Completed	A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. NCT00405756	Celgene Corporation	Phase 3
Terminated	Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderl NCT00644306	Central Hospital, Nancy, France	Phase 3